Markey Cancer Center

Screen%20Shot%202021-03-25%20at%203.39.05%20PM.png

DREAM Program Expands Community, Career Development for Health Equity Researchers from Underrepresented Minorities

Mar 26, 2021, 9:28 AM

The program has supported the training of underrepresented pre-docs, post-docs and assistant professors at the University of Kentucky committed to health equity research.

Markey Joins Nationwide Effort to Encourage Resumption of Cancer Screening, Treatment

Feb 1, 2021, 1:18 PM

The University of Kentucky Markey Cancer Center is teaming up with the National Comprehensive Cancer Network® (NCCN®), the American Cancer Society (ACS) and other leading cancer organizations across the country to endorse the resumption of cancer screening and treatment during the ongoing COVID-19 pandemic.

Markey Study Shows Kentucky Endometrial Cancer Patients Have Higher Rates of DACH1 Mutation

Jan 12, 2021, 8:18 AM

A new study by UK Markey Cancer Center researchers shows that DACH1 mutations are prevalent in Kentucky patients with endometrial cancer, suggesting that DACH1 may be a candidate biomarker for future trials with immunotherapy.

Williams Named Assistant Director for Cancer Health Equity at Markey

Nov 10, 2020, 8:22 AM

A major initiative of Williams and the Markey Community Impact Office will be the organization and expansion of Markey’s research and outreach portfolio that is focused on reducing cancer and other health disparities based on race/ethnicity, socioeconomic status, etc.

UK Study Shows FDA-approved Leukemia Drug May Help Treat Metastatic Melanoma

Oct 29, 2020, 8:29 AM

Building on these findings, Plattner and Markey oncologists are now collaborating with the pharmaceutical company Novartis to develop a Phase I clinical trial to test the safety and effectiveness of using nilotinib in relapsed melanoma patients.

UK Study Highlights Need for Genetic Testing for Kentucky Patients with Lung Cancer

Sep 23, 2020, 9:58 AM

Recently published in PLOS One, the study used Kentucky Cancer Registry patient data from 2007-2011 to identify trends in epidermal growth factor receptor (EGFR) mutation testing and the usage of the EGFR inhibitor, erlotinib.

Markey Joins National Cancer Consortium to Address the Impact of COVID-19 on Cancer

Sep 22, 2020, 8:12 AM

Markey has joined a consortium of 17 cancer centers across the country to better understand how COVID-19 has impacted cancer prevention, detection and care.

Cancer, COVID and the Kentucky Economy: How 'Sweet Annie' Could Make an Impact

Aug 11, 2020, 8:19 AM

Artemisia annua or "Sweet Annie" has been used as a medicinal herb for centuries. With potential to treat a variety of cancers & even COVID-19, this plant is more relevant than ever & UK is showing how we can take it from Kentucky fields to the lab to our patients.

Kuhs Named Co-Leader of Markey Cancer Prevention & Control Research Program

Aug 4, 2020, 8:21 AM

As a cancer prevention researcher trained in both basic laboratory science and epidemiology, Kuhs’ experience allows her to apply basic science findings to population-based studies, which will be essential to lowering cancer rates in the hardest-hit areas of the state.

UK Study Provides New Insight on Colorectal Cancer Growth

Jul 14, 2020, 8:40 AM

A group led by the Markey Cancer Center researcher Qing-Bai She discovered that SMS is overexpressed in colorectal cancers and plays an important role in balancing cellular spermidine levels that are a necessary adaptation for colorectal cancer growth.

Subscribe to Markey Cancer Center